MRNA Vaccines
Srishti Therapeutics
Overview
Srishti Therapeutics is developing mRNA vaccines targeting vector-borne diseases using hybrid antigen design. Supported by philanthropic grants, the project is advancing toward IND readiness and exploring new financial mechanisms to scale impact across underserved regions.
Focused on neglected diseases
01
Targets dengue, chikungunya, and other high-burden vector-borne illnesses lacking vaccine solutions.
Focused on neglected diseases
01
Targets dengue, chikungunya, and other high-burden vector-borne illnesses lacking vaccine solutions.
Hybrid antigen strategy
02
Combines traditional epitope mapping with novel mRNA payloads for broadened immune protection.
Hybrid antigen strategy
02
Combines traditional epitope mapping with novel mRNA payloads for broadened immune protection.
IND pipeline in motion
03
Backed by early philanthropic capital, now structuring toward regulatory and commercial readiness.
IND pipeline in motion
03
Backed by early philanthropic capital, now structuring toward regulatory and commercial readiness.
Modular bioscience, at your fingertips
Modular bioscience, at your fingertips
Modular bioscience, at your fingertips
MRNA Vaccines
Srishti Therapeutics
Overview
Srishti Therapeutics is developing mRNA vaccines targeting vector-borne diseases using hybrid antigen design. Supported by philanthropic grants, the project is advancing toward IND readiness and exploring new financial mechanisms to scale impact across underserved regions.
Focused on neglected diseases
01
Targets dengue, chikungunya, and other high-burden vector-borne illnesses lacking vaccine solutions.
Focused on neglected diseases
01
Targets dengue, chikungunya, and other high-burden vector-borne illnesses lacking vaccine solutions.
Hybrid antigen strategy
02
Combines traditional epitope mapping with novel mRNA payloads for broadened immune protection.
Hybrid antigen strategy
02
Combines traditional epitope mapping with novel mRNA payloads for broadened immune protection.
IND pipeline in motion
03
Backed by early philanthropic capital, now structuring toward regulatory and commercial readiness.
IND pipeline in motion
03
Backed by early philanthropic capital, now structuring toward regulatory and commercial readiness.
Modular bioscience, at your fingertips
Modular bioscience, at your fingertips
Modular bioscience, at your fingertips